Prime Medicine (PRME) Capital Expenditures (2021 - 2026)
Prime Medicine's (PRME) quarterly Capital Expenditures came in at $290000.0 in Q4 2025, down 72.2% YoY from $1.0 million in Q4 2024, and down 92.91% on a QoQ basis from $4.1 million in Q3 2025.
Prime Medicine (PRME) Capital Expenditures (2021 - 2026) Analysis & Trends
Prime Medicine (PRME) has 5 years of Capital Expenditures data on file, last reported at $290000.0 in Q4 2025.
- Quarterly Capital Expenditures fell 72.2% year-over-year to $290000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $2.1 million (down 23.11% YoY) and the FY2025 annual result came in at $4.5 million, up 292.63% from the prior year.
- Capital Expenditures slipped to $290000.0 in Q4 2025, from $4.1 million in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $8.2 million in Q4 2023 to a low of -$10.3 million in Q4 2022.
- A 5-year average of $948941.2 and a median of $1.0 million in 2024 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 363.64% in 2024, down 1967.84% in 2024.
- Tracing PRME's Capital Expenditures over 5 years: stood at $754000.0 in 2021, then plunged by 1467.64% to -$10.3 million in 2022, then soared by 179.63% to $8.2 million in 2023, then plunged by 87.3% to $1.0 million in 2024, then slumped by 72.2% to $290000.0 in 2025.
- The last three Capital Expenditures figures came in at $290000.0 (Q4 2025), $4.1 million (Q3 2025), and -$2.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - | 46,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 46,000.00 |
| Jun 30, 2026 | 46,000.00 |
| Mar 31, 2026 | 214,000.00 |
| Mar 31, 2026 | 214,000.00 |
| Dec 31, 2025 | 290,000.00 |
| Dec 31, 2025 | 290,000.00 |
| Sep 30, 2025 | 4.09 Mn |
| Sep 30, 2025 | 4.09 Mn |
| Jun 30, 2025 | -2.27 Mn |
| Jun 30, 2025 | -2.27 Mn |
| Mar 31, 2025 | 2.42 Mn |
| Mar 31, 2025 | 2.42 Mn |
| Dec 31, 2024 | 1.04 Mn |
| Dec 31, 2024 | 1.04 Mn |
| Sep 30, 2024 | -4.12 Mn |
| Sep 30, 2024 | -4.12 Mn |
| Jun 30, 2024 | 3.39 Mn |
| Jun 30, 2024 | 3.39 Mn |
| Mar 31, 2024 | 833,000.00 |
| Mar 31, 2024 | 833,000.00 |